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Chagas disease (ChD) affects approximately 10million individuals in
Latin America and, due to immigration it is also of increasing
importance in North America and Europe. Chronic cardiomyopathy,
observed in 20–40% of the cases, is the most important and lethal
complication of ChD [1]. Control of the transmission by the use of
insecticides and aging of the individuals infected in early adulthood are
making ChD a health burden in the elderly in old endemic areas. As the
prevalence of overweight/obesity in this age group has been increasing,
the two conditions are likely to co-exist in older individuals [2].
The “obesity paradox” (i.e., longer survival of overweight/obese
individuals in comparison to lean ones) has been described in older
adults with and without cardiovascular diseases (CVD) [3]. The
etiology of heart disease (HD) might have inﬂuence on the
phenomenon [4]. Whether overweight/obesity are protective deter-
minants of mortality in subjects with Chagas disease (ChD) is still
unknown.
Our aim was to investigate the relationship between body mass
index (BMI), waist circumference (WC) and death, in relation to heart
disease (HD), among elderly participants with a high prevalence of ChD
in the Bambuí (Brazil) Cohort Study of Aging (BHAS).
The BHAS, a cohort study of elderly residents in the Bambuí City
(Minas Gerais, southeast of Brazil) is described in detail elsewhere [5],
and was approved by the ethics board of the Fundação Oswaldo Cruz,
Belo Horizonte, Brazil. An informed consent formwas obtained from all
participants. The authors of this manuscript have certiﬁed that they
comply with the Principles of Ethical Publishing.
The outcome of the present analysis was overall death from
baseline (1997) to 2007. Trypanosoma cruzi infection, anthropometric
measurements (AM) assessment, B-type natriuretic (BNP) test, and
deﬁnitions of other measurements performed were detailed pre-
viously [5]. AM were repeated in the surviving participants in 2000
and 2002. Underweight (BMIb18.5 kg/m2; n=104; 7.2%) subjects
were excluded. ECGs were codiﬁed according to the Minnesota code
(MC) [6] and classiﬁed as abnormal in the presence of major
abnormalities [7] or of frequent supraventricular and ventricular
premature beats (MC 8.1.1, 8.1.2 or 8.1.3). HD was deﬁned by the
combination of an abnormal ECG and augmented BNP levels. As BNP
levels are inversely related to BMI and WC levels in the BHAS [8], we
used distinct cut-off points according to BMI classiﬁcation: 106 pg/mL
in the normal and 128 pg/mL in the high BMI group.
Survival rates were compared across the groups formed according
to HD status, and to normal (18.5≤BMIb25 kg/m2) or high BMI
(BMI≥25 kg/m2), and low (b88 cm for women, b102 cm for men) or
high WC (≥88 cm for women, ≥102 cm for men) by Kaplan–Meier
(KM) curves and log-rank tests. Overall, 7.2% of all values were
missing. We performed multiple imputation of missing values with
generation of ﬁve complete datasets [9]. Hazard ratios (HR) and 95%
conﬁdence intervals (CI) of death according to BMI/WC (continuous)
at various time-points were estimated by extended Cox regression
models [10]. Each model was additionally adjusted for a set of
demographic, clinical, socioeconomic and behavioral determinants of
death, as well as for a product term of interaction between BMI/WC
and HD status. Subsequently, we stratiﬁed by ChD, and excluded
subjects with probable cachexia (≥10% weight loss weight and death
within the ﬁrst ﬁve years of follow-up). Absolute rates of death per
unit of BMI were estimated by KM curves.
After exclusions and losses to follow-up (78; 5.8%),1271 participants
entered the analysis, 208 (16.4%) of whom had HD. These were older
(70.4, SD: 6.7 versus 68.1, SD: 7.2 years; p=0.003) and had a higher
prevalence of ChD (137, 65.9% versus 320, 30.0%; pb0.001). Differences
between the groups with and without HD in relation to BMI status are
depicted in Table 1.
Mean follow-up time was 9.0 years. Deaths occurred in 128 (61.5%)
and 310 (29.2%) subjects with and without HD, respectively. High BMI/
WC were associated with the lowest survival rates at 10-year follow-up
regardless of HD status (Figs. 1 and 2). After full adjustment, the
relationship between mortality and BMI and WC, was U-shaped and
non-signiﬁcant, respectively. These results were similar after exclusion
of participants with probable cachexia, and regardless of HD and ChD
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status (Table 2). BMI between 30 and 32 kg/m2 was associated with the
lowest absolutemortality rates at 10-year follow-up in participants with
(46–47%) and without HD (20–21%).
Our results are similar to studies which found a protective role of
overweight/obesity in the prognosis of subjects with HD [4,11]. Regarding
the association between WC and mortality, previous ﬁndings in popu-
lations with HF are heterogeneous [12,13]. Not only high BMI being a
marker of greater muscle mass, but also beneﬁts associated with high fat
mass, such as an increased strength capacity can explain these ﬁndings
[14]. Neither reverse causationdue to cachexia in elderlywith normal BMI
nor neutralization of the inﬂammatory effects of tumor necrosis factor
(TNF)-alpha by soluble receptors in the adipose tissue [3] seems plausible
explanations to our results, as suggested by the sensitivity analysis and by
thehighest CRP levels in subjectswithbothhighBMIandHD, respectively.
A healthier status of overweight/obese in comparison to lean subjectswas
not observed either.
Our study is unique in investigating the “obesity paradox” in older
adultswithChD. Theuse of bothBMI andWCdirectlymeasured at various
time-points, the exclusion of subjects with underweight and probable
cachexia, the long-term follow-upwithminimal numberof losses, and the
high rate of events are major strengths. Limitations due to the small
number of subjects with BMI≥40 kg/m2 (12; 1.1%), and to the lack of
Table 1
Baseline characteristics, according to groups with and without HD and with normal or high BMI levels.
Characteristics Without HD
(n 1063; 83.6%)
With HD
(n 208; 16.4%)
Normal BMI
(478; 37.6%)
Normal BMI
(585; 46.0%)
Differences*
(95% CI)
Normal BMI
(107; 8.4%)
High BMI
(101; 7.9%)
Differences*
(95% CI)
Age† (years) 68.7 67.7 1.0 71.6 69.0 2.6
(7.0) (6.5) (0.2, 1.8) (7.6) (6.5) (0.7, 4.5)
Female sex‡ 252 403 −16.5% 55 75 −22.9%
(51.6) (68.1) (−22.2, −10.6) (51.4) (74.3) (−35.6, −10.1)
BMI (kg/m2)§ 22.6 28.2 – 21.9 27.7 –
(20.9, 23.8) (26.5, 30.5) (20.6, 23.4) (26.4, 29.5)
BMI (kg/m2)† 22.3 29.1 −6.7 22.0 28.7 −6.7
(1.7) (3.8) (−7.1, −6.5) (1.8) (3.7) (−7.5, −5.9)
WC (cm) 86 99 −13.0 85.2 98.9 −13.7
(7.1) (9.1) (−14.0, −12.1) (6.6) (8.4) (−15.7, −11.8)
Chagas disease‡ 161 157 6.9% 79 58 16.4%
(33.7) (26.8) (1.3, 12.4) (73.8) (57.4) (3.7, 29.1)
Smoking‡ 106 (22.2) 58 12.3% 26 10 14.4
(9.9) (7.8, 16.7) (24.3) (9.9) (4.4, 24.4)
BNP (pg/dL)§ 66.0 59.0 – 225.0 189.0 –
(38, 113) (32, 97) (162, 321) (139, 265)
BNP (pg/dL)† 100.8 88.2 12.6 305.8 258.5 47.3
(137.4) (118.0) (−3.0, 28.2) (268.5) (234.5) (−21.1, 115.7)
CRP (mg/dL)§ 2.31 3.94 – 3.15 4.94 –
(1.06, 4.92) (1.84, 6.88) (1.27, 7.29) (2.30, 8.66)
CRP (pg/dL)† 4.73 6.01 −1.3 5.82 8.09 −2.3
(9.39) (10.12) (−2.5, −0.1) (8.33) (1.20) (−5.0, 0.4)
Systolic blood pressure (mm Hg)† 136 138 −2.4 141 144 −3.8
(23) (20) (−5.0, 0.3) (26) (26) (−10.8, 3.2)
Diabetes mellitus‡ 47 117 −10.1% 11 19 −8.5%
(9.9) (20.0) (−14.3, −5.9) (10.3) (18.8) (−18.1, 1.0)
Digoxin use‡ 53 75 −1.7% 27 23 2.4%
(11.1) (12.8) (−5.6, 2.2) (25.2) (22.8) (−9.1, 14.1)
Anti-hypertensive medication use‡ 176 360 −24.7% 59 69 −13.2%
(36.8) (61.5) (−30.6, −18.9) (55.1) (68.3) (−26.3, −0.1)
Serum creatinine (mg/dL)§ 0.85 0.83 – 0.90 0.90 –
(0.75, 0.97) (0.73, 0.97) (0.79, 1.09) (0.79, 1.08)
Serum creatinine (mg/dL)† 0.90 0.86 −0.02 0.99 0.95 0.00
(0.35) (0.20) (−0.07, 0.00) (0.49) (0.29) (−0.08, 0.14)
Total cholesterol (mg/dL)† 231 239 −7.9 233 234 −0.8
(49) (49) (−13.8, −1.9) (53) (47) (−14.3, 12.8)
Physically active‡ 98 156 −6.2% 19 21 −3.0%
(20.2) (26.4) (−11.3, −1.2) (17.8) (20.8) (−13.8, 7.7)
Family income‡
Lower 337 342 11.5% 84 78 1.3%
(69.9) (58.4) (5.8, 17.3) (78.5) (77.2) (−10.0, 12.6)
Intermediate 110 176 −7.2% 19 19 −1.1%
(22.8) (30.0) (−12.5, −1.9) (17.8) (18.8) (−11.6, 9.5)
Higher 35 68 −4.3% 4 4 −0.2%
(7.3) (11.6) (−7.8, −0.9) (3.7) (4.0) (−5.5, 5.0)
Education‡
Lower 160 128 11.3% 50 41 6.1%
(32.9) (21.6) (6.0, 16.6) (46.7) (40.6) (−7.3, 19.6)
Intermediate 278 368 −5.0% 52 55 −5.9%
(57.2) (62.2) (−10.8, 0.9) (48.6) (54.5) (−19.4, 7.7)
Higher 48 96 −6.3% 5 5 −0.3%
(9.9) (16.2) (−10.3, −2.4) (4.7) (5.0) (−6.1, 5.5)
HD heart disease; BMI body mass index; WC waist circumference; BNP B-type natriuretic peptide; CRP C-reactive protein.
*Differences between means and proportions; continuous variables are described by means (SD)† or median (IQR)§ and categorical variables by frequencies (%)‡.
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more accurate measurements of fat mass and left ventricle ejection
function warrant mention.
In conclusion, high BMI levels are associated with higher survival
regardless of HD status in an elderly population with a high prevalence
of ChD, whereas high WC values do not inﬂuence on mortality. The
“obesity paradox” should be taken into account whenweight control is
planned for elderly subjects with HD and ChD.
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Lead aVR is recorded with positive input from the right arm
electrode and negative input averaged from the left arm and left leg
electrodes. It is arithmetically and geometrically reciprocal to standard
leads I and II combined. Interpretation of aVR's unique orientation
(with no contiguous lead) has been controversial. In the Swedish
CABRERA display format aVR is displayed as mirror image (i.e., -aVR)
between standard leads I and II. This CABRERA display in the frontal
plane (aVL, I, -aVR, II, aVF, III) was supported by the 2007 Universal
Deﬁnition of Myocardial Infarction document as offering more
accurate spatial contiguity [1]. The 2002 ACC/AHA exercise testing
guidelines also downplayed the value of aVR in interpreting exercise
induced ischemia [2]. However, a recent collaborative international
meta-analysis including 22,740 patients [3] found that aVR ST
elevation independently predicted left main or 3-vesssel disease. The
current article extends prior reviews [3,4] and also evaluates the
impact of aVR ST changes on clinical outcome.
If one accepts aVR as facing the inside of left ventricular cavity and
“reciprocal” to V5 (positioned in the anterior axillary line) and V6
(positioned in themid axillary line), aVR should also be “reciprocal” to
V7 (positioned in the posterior axillary line). V7 captured changes in
the postero-apical part of the left ventricle but is not recorded on a
standard 12-lead ECG. The reciprocal lead aVR will therefore contain
unique information.
Comparing recordings on aVR with those on unipolar leads V5–7
referenced to the Wilson's Central Terminal (reﬂecting an iso-electric
point inside the heart) is challenging, because the amplitudes of both
QRS complex andSTdeviation inV5–7 are dependenton thedistanceand
nature of the conducting medium between the recording electrode and
the epicardium [5,6]. As previously reviewed, lower amplitudes of ST
changes are found in leads farther from the heart (V7–9) than in the
standard chest leads closer to the heart (V1–4) during balloon coronary
occlusion models [6]. Amplitude of ST changes from similar amount of
ischemia varies among the chest leads and is lower for leads farther
away.
With left ventricular sub-endocardial ischemia during stress test,
ST depression may be observed in V5–7 and ST elevation in aVR. Not
only is V7 not routinely recorded, ST depression in leads V5,6 may also
be inconspicuous because of their longer distance from the heart, such
as in patients with emphysema. A recent article [7] reported 454
stable patients in whom rest and stress ECG, clinical parameters, and
single photon emission computed tomographic myocardial perfusion
imaging (MPI) data were correlated with angiographic data—75 had
left main or ostial left anterior descending (LAD) disease, 276 had
coronary disease in other sites and 103 had no disease. While ST
depression in inferolateral leads was always signiﬁcant on univariate
analysis to predict left main and ostial LAD disease, the predictive
ability measured by the area under the curve (AUC) on logistic
regression was much lower than aVR ST elevation. The AUC was 0.62
for V4, 0.69 for V5, 0.70 for V6, 0.65 for II, 0.58 for III, 0.61 for aVF; and
was 0.82 for aVR. Onmultivariate analysis, the strongest predictor was
stress-induced ST elevation in lead aVR (pb0.0001), while left
ventricular ejection fraction after stress and percent reversible LAD
ischemia on MPI also contributed (pb0.005 and pb0.05 respectively).
However, the univariate AUC was much lower at 0.60 and 0.64
respectively.
In the collaborative international meta-analysis [3], 4844 patients
with stable angina underwent stress tests. Transient ischemic dilatation
during stress test, ST elevation in aVR and V1 and hyperlipidemia were
the most powerful predictors of left main or multi-vessel disease.
In the classical non-ST elevation acute coronary syndrome (ACS)
the left ventricle is having subendocardial ischemia. Mechanistic
explanation for aVR ST elevation is similar to stress induced ischemia.
Table 1 reviews clinical outcomes in 4 recent studies [8–11]. A graded
univariable relationship between aVR ST elevation and mortality is
almost always observed. In the GRACE registry, aVR ST elevation did
not add signiﬁcantly to the GRACE score in prognostication [10].
However, the GRACE score contains age and creatinine, two strong
prognosticators that do not indicate myocardial ischemia. Lead aVR ST
elevation does and ischemia is potentially reversible with therapy.
Using GRACE score to separate patients to low, medium and high
risk, Tanglieri [11] reported that aVR ST elevation further stratiﬁed in-
hospital mortality.
Because aVR is the only lead that faces directly the high inter-
ventricular septum, an isolated transmural infarction theremay not be
diagnosed as STEMI because there is no lead contiguous to aVR [4].
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